FTC Report Shows Pharma Mergers Are Most Likely To Face Challenges

Of 122 deals involving pharmaceutical markets investigated over a five-year period, the FTC sought some kind of relief (such as a divestiture) in 119 of them.

This article requires premium access

This article requires premium access to The New Jersey Law Journal. Please sign in or subscribe to read the full text.